Equities analysts expect Haemonetics Corporation (NYSE:HAE) to post $0.44 earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Haemonetics’ earnings, with the highest EPS estimate coming in at $0.46 and the lowest estimate coming in at $0.41. Haemonetics reported earnings of $0.43 per share during the same quarter last year, which suggests a positive year over year growth rate of 2.3%. The business is expected to report its next quarterly earnings report on Monday, February 5th.

On average, analysts expect that Haemonetics will report full-year earnings of $1.70 per share for the current year, with EPS estimates ranging from $1.67 to $1.72. For the next fiscal year, analysts forecast that the firm will post earnings of $1.86 per share, with EPS estimates ranging from $1.75 to $1.95. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Haemonetics.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.07. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The business had revenue of $225.40 million for the quarter, compared to the consensus estimate of $219.12 million. During the same period in the previous year, the business earned $0.38 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis.

Several brokerages have recently commented on HAE. Zacks Investment Research downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, November 20th. Morgan Stanley boosted their price objective on Haemonetics from $43.00 to $51.00 and gave the company an “equal weight” rating in a research report on Thursday, November 9th. Craig Hallum reiterated a “hold” rating and issued a $50.00 target price (up from $40.00) on shares of Haemonetics in a research report on Wednesday, November 8th. Finally, Barrington Research boosted their target price on Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. Haemonetics currently has a consensus rating of “Hold” and an average target price of $53.33.

Shares of Haemonetics (NYSE:HAE) traded up $0.14 during trading on Tuesday, hitting $56.62. The stock had a trading volume of 477,100 shares, compared to its average volume of 358,578. Haemonetics has a fifty-two week low of $36.44 and a fifty-two week high of $58.99. The stock has a market capitalization of $2,983.17, a P/E ratio of 34.65, a price-to-earnings-growth ratio of 4.25 and a beta of 0.99. The company has a quick ratio of 1.51, a current ratio of 2.17 and a debt-to-equity ratio of 0.22.

In other Haemonetics news, Director Pedro P. Granadillo sold 7,118 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $57.06, for a total transaction of $406,153.08. Following the sale, the director now directly owns 31,663 shares in the company, valued at $1,806,690.78. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ronald G. Gelbman sold 5,440 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $56.69, for a total value of $308,393.60. The disclosure for this sale can be found here. Insiders sold 47,368 shares of company stock worth $2,602,393 over the last quarter. 1.20% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. Tudor Investment Corp ET AL raised its position in Haemonetics by 0.5% during the second quarter. Tudor Investment Corp ET AL now owns 28,126 shares of the medical instruments supplier’s stock valued at $1,111,000 after purchasing an additional 143 shares during the period. Arizona State Retirement System grew its stake in shares of Haemonetics by 1.1% during the second quarter. Arizona State Retirement System now owns 27,397 shares of the medical instruments supplier’s stock valued at $1,082,000 after buying an additional 300 shares during the last quarter. Strs Ohio grew its stake in shares of Haemonetics by 1.0% during the second quarter. Strs Ohio now owns 29,300 shares of the medical instruments supplier’s stock valued at $1,157,000 after buying an additional 300 shares during the last quarter. Amalgamated Bank grew its stake in shares of Haemonetics by 5.7% during the second quarter. Amalgamated Bank now owns 7,322 shares of the medical instruments supplier’s stock valued at $289,000 after buying an additional 392 shares during the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Haemonetics by 0.9% during the second quarter. American Century Companies Inc. now owns 46,271 shares of the medical instruments supplier’s stock valued at $1,827,000 after buying an additional 425 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “$0.44 EPS Expected for Haemonetics Corporation (HAE) This Quarter” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/12/0-44-eps-expected-for-haemonetics-corporation-hae-this-quarter.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Get a free copy of the Zacks research report on Haemonetics (HAE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.